0000950170-24-008051.txt : 20240126
0000950170-24-008051.hdr.sgml : 20240126
20240126191141
ACCESSION NUMBER: 0000950170-24-008051
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240124
FILED AS OF DATE: 20240126
DATE AS OF CHANGE: 20240126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galimi Francesco
CENTRAL INDEX KEY: 0001823996
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 24569680
MAIL ADDRESS:
STREET 1: 12930 VIA ESPERIA
CITY: DEL MAR
STATE: CA
ZIP: 92014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
ownership.xml
4
X0508
4
2024-01-24
0001720580
Adicet Bio, Inc.
ACET
0001823996
Galimi Francesco
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
false
true
false
false
SVP & Chief Medical Officer
false
Common Stock
2024-01-24
4
F
false
4957
2.40
D
75501
D
Common Stock
2024-01-24
4
A
false
26300
0.00
A
101801
D
Stock Option (Right to Buy)
2.40
2024-01-24
4
A
false
288134
0.00
A
2034-01-23
Common Stock
288134
288134
D
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
/s/ Nick Harvey, Attorney-in-Fact
2024-01-26